Michael J. Reardon

Michael J. Reardon is an American cardiac surgeon and medical researcher. He is known for his work in heart autotransplantation for cancerous heart tumor, an operation in which the surgeon removes the patient’s heart, cuts out the malignant tumor, and reimplants the heart back in the patient’s chest. [1][2] He performed the first successful heart autotransplantation for a cancerous heart tumor in 1998.

Education

Reardon received his medical education from Baylor College of Medicine where he graduated with honors in 1978. He received his general surgery residency at Baylor College of Medicine in 1983, and completed a thoracic surgery fellowship training at Texas Heart Institute in 1985 under the tutelage of Dr. Denton Cooley.

Career

Reardon's career includes accomplishments as an attending physician and medical school professor in Houston, Texas. He joined the staff of the Houston Methodist Hospital in 1985 following his cardiac fellowship. He became a faculty member of Baylor College of Medicine in 1993. He was appointed as Chief of Cardiac Surgery and Professor of Cardiothoracic Surgery of Weill Cornell Medical College and Houston Methodist Hospital in 1995. He currently holds the position of Clinical Professor of Cardiothoracic Surgery at MD Anderson Cancer Center and created the multi-institution, multidisciplinary cardiac tumor team with Houston Methodist Hospital and MD Anderson Cancer Center.

Honors and Awards

Reardon has received numerous awards including the Overstreet Award and Noon Award. He currently holds the Allison Family Distinguished Chair of Cardiovascular Research and is divides his time between building innovative clinical, research and educational programs.[3]

Research Interests and Contributions

Reardon’s research interests have focused on aortic surgery, cardiac valve surgery and cardiac tumors. He has served on the national steering committee for the CoreValve, SurTAVI and reprise III TAVR trials and as national surgical principal investigator on the SurTAVI trial, reprise III trial and the Gore type A dissection trial. He is currently on the national steering and screening committees for the Medtronic CoreValve US Pivotal Trial and the international steering committee for the SurTAVI Trial, for which he is also a national surgical principal investigator.[4] He has given numerous research presentation and published extensively in areas including cardiac tumor treatment, catheter based approaches to structural heart disease, catheter based and open aortic disease treatment. He has published more than 300 articles and abstracts, and also service as a reviewer for journals including the Annals of Thoracic Surgery and Circulation. He is the associate editor of surgery for the Methodist DeBakey Cardiovascular Journal.

References

  1. ↑ "Rare Heart Surgery Saves Life of New York Woman".
  2. ↑ "A Desperate Gamble for Surgeon and Patient".
  3. ↑ "Michael Reardon, MD - Houston Methodist". houstonmethodist.pure.elsevier.com. Retrieved 2015-09-15.
  4. ↑ "Michael Reardon, MD on CoreValve".

External links


This article is issued from Wikipedia - version of the 10/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.